IPL344 for ALS

ipl344 als iplIPL344 has been evaluated in 2 consecutive clinical studies in patients with amyotrophic lateral sclerosis (ALS) to assess the safety, tolerability pharmacokinetics and primary efficacy of the drug. The first study was a phase 1/2a, open-label, 28 days of dose-escalating study. By the end of this part of the study, the participants could continue to the ongoing phase 2a study up to 36 months. The drug is given daily as bolus intravenous administration in a short and simple procedure at patient’s home by family and caregivers.

The study was conducted at the ALS Clinic of the Neurology Department of the Hadassah Medical Center in Jerusalem, Israel according to the approval and guidelines of the Israeli ministry of health.

Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients

Read the Press Release